Promoting Smoking Cessation in Campus
Launched by BEIJING NORMAL UNIVERSITY · Mar 8, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help people stop smoking by using a chatbot on their smartphones. The goal is to see if this digital support can effectively assist smokers in quitting and to understand how well this program can be put into practice in the community. The study is currently looking for participants who are at least 18 years old, live in Zhuhai for the next six months, and smoke at least one cigarette or use e-cigarettes daily. Additionally, participants need to have a smartphone and be comfortable using WeChat, a popular messaging app.
If you decide to join the study, you can expect to receive support through the chatbot, which will guide you in your journey to quit smoking. This program aims to make the quitting process easier and more accessible for everyone involved. However, those who have difficulties communicating or are already part of another smoking cessation program cannot participate. This trial is an exciting opportunity for smokers looking for help to quit in a modern and tech-friendly way.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. aged 18 and above, reside in Zhuhai for the next 6 months;
- • 2. smoke at least 1 cigarette or use e-cigarettes daily;
- • 3. Having a smartphone and a WeChat account, being able to use WeChat skillfully.
- Exclusion Criteria:
- • 1. Smokers who have communication barrier (either physically or cognitively);
- • 2. Smokers who are currently participating in other SC programmes or services
About Beijing Normal University
Beijing Normal University is a prestigious academic institution in China, renowned for its commitment to advancing research and education across various disciplines, including the fields of health and life sciences. As a clinical trial sponsor, the university leverages its extensive expertise, state-of-the-art facilities, and collaborative networks to facilitate innovative research initiatives. By fostering partnerships with healthcare institutions and industry stakeholders, Beijing Normal University aims to contribute to the development of cutting-edge therapeutic solutions, enhance patient outcomes, and promote public health through rigorous clinical investigations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhuhai, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials